Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Moderna Inc (NASDAQ: MRNA) closed at $24.50 in the last session, down -8.14% from day before closing price of $26.67. In other words, the price has decreased by -$8.14 from its previous closing price. On the day, 12.64 million shares were traded. MRNA stock price reached its highest trading level at $25.9 during the session, while it also had its lowest trading level at $23.7.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Bancel Stephane bought 160,314 shares for $31.22 per share. The transaction valued at 5,004,318 led to the insider holds 9,210,686 shares of the business.
SAGAN PAUL bought 31,620 shares of MRNA for $1,004,251 on Mar 03 ’25. The Director now owns 312,027 shares after completing the transaction at $31.76 per share. On Dec 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 529 shares for $44.68 each. As a result, the insider received 23,637 and left with 20,446 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 10311216128 and an Enterprise Value of 3409836544. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.92 while its Price-to-Book (P/B) ratio in mrq is 0.87. Its current Enterprise Value per Revenue stands at 1.054 whereas that against EBITDA is -0.908.
Stock Price History:
The Beta on a monthly basis for MRNA is 2.00, which has changed by -0.76697737 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -24.33%, while the 200-Day Moving Average is calculated to be -58.37%.
Shares Statistics:
According to the various share statistics, MRNA traded on average about 11.79M shares per day over the past 3-months and 12642850 shares per day over the past 10 days. A total of 386.00M shares are outstanding, with a floating share count of 341.66M. Insiders hold about 11.44% of the company’s shares, while institutions hold 70.77% stake in the company. Shares short for MRNA as of 1741910400 were 46881859 with a Short Ratio of 4.22, compared to 1739491200 on 42296108. Therefore, it implies a Short% of Shares Outstanding of 46881859 and a Short% of Float of 16.84.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
